stockrowAccendra Health, Inc.
ACH Healthcare Medical Distribution
Accendra Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.8 billion, up 3.06% from fiscal 2024.
- Revenue
- −10.1%
- EPS
- +89.7%
- Free cash flow
- −1,624.8%
- Total debt
- −13.1%
Quarter to June 2026, against a year earlier
Follow ACH
Alert me
Accendra Health, Inc. (ACH) EV/Sales
As of 5 November 2026, Accendra Health, Inc. (ACH) trades at a EV/Sales of 0.9×. Over the past ten years it has ranged from 0.2× (March 2020) to 1.1× (January 2025); the current reading is higher than 92% of that period. That is in line with the Medical Distribution industry median of 0.9× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.7× | (31.68%) |
| FY2024 | 1.1× | 227.82% |
| FY2023 | 0.3× | (17.98%) |
| FY2022 | 0.4× | (6.71%) |
| FY2021 | 0.4× | 34.04% |
| FY2020 | 0.3× | 61.05% |
| FY2019 | 0.2× | (15.54%) |
| FY2018 | 0.2× | (0.91%) |
| FY2017 | 0.2× | (19.45%) |
| FY2016 | 0.3× | (1.10%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.0× | 35.03% |
| Mar 2026 | 0.7× | (0.49%) |
| Dec 2025 | 0.7× | (19.58%) |
| Sep 2025 | 0.9× | (7.41%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| HKPD Cellyan Biotechnology Co., Ltd compare | n/m |
| YI 111, Inc. Sponsored ADR compare | 0.0× |
| COSM Cosmos Health Inc. compare | 0.4× |
| HSIC Henry Schein, Inc. compare | 0.9× |
| ACH Accendra Health, Inc. | 0.9× |
| SNYRQ Synergy CHC Corp. compare | 0.9× |
| AHG Akso Health Group Sponsored ADR compare | 1.7× |
| FOCL FocalTherics compare | 2.3× |
| MEDS DataMeds AI, Inc compare | 2.5× |
| Medical Distribution industry median | 0.9× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)